Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma.

Lassman AB, Aldape KD, Ansell PJ, Bain E, Curran WJ, Eoli M, French PJ, Kinoshita M, Looman J, Mehta M, Muragaki Y, Narita Y, Ocampo C, Roberts-Rapp L, Song M, Vogelbaum MA, Walenkamp AME, Wang TJC, Zhang P, van den Bent MJ.

J Neurooncol. 2019 Jul 4. doi: 10.1007/s11060-019-03222-y. [Epub ahead of print]

PMID:
31273577
2.

Letter: When Less is More: Dexamethasone Dosing for Brain Tumors.

Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, Lassman AB, Liau LM, Mason W, McFaline-Figueroa JR, Mehta MP, Mellinghoff IK, Nabors LB, Nayak L, Reardon DA, Wen PY.

Neurosurgery. 2019 Jun 19. pii: nyz186. doi: 10.1093/neuros/nyz186. [Epub ahead of print] No abstract available.

PMID:
31215634
3.

Sequencing and curation strategies for identifying candidate glioblastoma treatments.

Frank MO, Koyama T, Rhrissorrakrai K, Robine N, Utro F, Emde AK, Chen BJ, Arora K, Shah M, Geiger H, Felice V, Dikoglu E, Rahman S, Fang A, Vacic V, Bergmann EA, Vogel JLM, Reeves C, Khaira D, Calabro A, Kim D, Lamendola-Essel MF, Esteves C, Agius P, Stolte C, Boockvar J, Demopoulos A, Placantonakis DG, Golfinos JG, Brennan C, Bruce J, Lassman AB, Canoll P, Grommes C, Daras M, Diamond E, Omuro A, Pentsova E, Orange DE, Harvey SJ, Posner JB, Michelini VV, Jobanputra V, Zody MC, Kelly J, Parida L, Wrzeszczynski KO, Royyuru AK, Darnell RB.

BMC Med Genomics. 2019 Apr 25;12(1):56. doi: 10.1186/s12920-019-0500-0.

4.

Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines.

Chang SM, Messersmith H, Ahluwalia M, Andrews D, Brastianos PK, Gaspar LE, Gatson NN, Jordan JT, Khasraw M, Lassman AB, Maues J, Mrugala M, Raizer J, Schiff D, Stevens G, Sumrall A, Van den Bent M, Vogelbaum MA.

Neuro Oncol. 2019 Mar 18;21(4):424-427. doi: 10.1093/neuonc/noz034.

PMID:
30883663
5.

Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines.

Chang SM, Messersmith H, Ahluwalia M, Andrews D, Brastianos PK, Gaspar LE, Gatson NTN, Jordan JT, Khasraw M, Lassman AB, Maues J, Mrugala M, Raizer J, Schiff D, Stevens G, Sumrall A, van den Bent M, Vogelbaum MA.

J Clin Oncol. 2019 May 1;37(13):1130-1135. doi: 10.1200/JCO.18.02085. Epub 2019 Mar 18.

PMID:
30883246
6.

Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma.

Lassman AB, Roberts-Rapp L, Sokolova I, Song M, Pestova E, Kular R, Mullen C, Zha Z, Lu X, Gomez E, Bhathena A, Maag D, Kumthekar P, Gan HK, Scott AM, Guseva M, Holen KD, Ansell PJ, van den Bent MJ.

Clin Cancer Res. 2019 Jun 1;25(11):3259-3265. doi: 10.1158/1078-0432.CCR-18-3034. Epub 2019 Feb 22.

PMID:
30796037
7.

Chemotherapy Treatment and Trials in Low-Grade Gliomas.

Donovan LE, Lassman AB.

Neurosurg Clin N Am. 2019 Jan;30(1):103-109. doi: 10.1016/j.nec.2018.08.007. Review.

PMID:
30470397
8.

Magnetic Resonance Imaging-Based Screening for Asymptomatic Brain Tumors: A Review.

Neugut AI, Sackstein P, Hillyer GC, Jacobson JS, Bruce J, Lassman AB, Stieg PA.

Oncologist. 2019 Mar;24(3):375-384. doi: 10.1634/theoncologist.2018-0177. Epub 2018 Oct 10. Review.

PMID:
30305414
9.

Clinical Reasoning: Transient speech deficits in a patient with history of medulloblastoma.

Schulte JD, Hargus G, Canoll P, Sisti MB, Wang TJC, Lignelli A, Lassman AB.

Neurology. 2018 Sep 18;91(12):e1196-e1201. doi: 10.1212/WNL.0000000000006202. No abstract available. Erratum in: Neurology. 2018 Nov 27;91(22):1031.

PMID:
30224509
10.

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.

Lassman AB, van den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Ansell PJ, Bain E, Holen KD, Maag D, Merrell R.

Neuro Oncol. 2019 Jan 1;21(1):106-114. doi: 10.1093/neuonc/noy091.

11.

Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

Camidge DR, Lee EQ, Lin NU, Margolin K, Ahluwalia MS, Bendszus M, Chang SM, Dancey J, de Vries EGE, Harris GJ, Hodi FS, Lassman AB, Macdonald DR, Peereboom DM, Schiff D, Soffietti R, van den Bent MJ, Wefel JS, Wen PY.

Lancet Oncol. 2018 Jan;19(1):e20-e32. doi: 10.1016/S1470-2045(17)30693-9. Review.

PMID:
29304358
12.

Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma.

Reardon DA, Lassman AB, Schiff D, Yunus SA, Gerstner ER, Cloughesy TF, Lee EQ, Gaffey SC, Barrs J, Bruno J, Muzikansky A, Duda DG, Jain RK, Wen PY.

Cancer. 2018 Apr 1;124(7):1438-1448. doi: 10.1002/cncr.31172. Epub 2017 Dec 19.

13.

Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma.

Smith DR, Wu CC, Saadatmand HJ, Isaacson SR, Cheng SK, Sisti MB, Bruce JN, Sheth SA, Lassman AB, Iwamoto FM, Wang SH, Canoll P, McKhann GM 2nd, Wang TJC.

J Neurooncol. 2018 Apr;137(2):303-311. doi: 10.1007/s11060-017-2718-z. Epub 2017 Dec 20.

PMID:
29264835
14.

Local control and overall survival for adjuvant stereotactic radiosurgery in patients with residual or recurrent disease.

Nanda T, Yaeh A, Wu CC, Jani A, Saad S, Qureshi YH, Cauley KA, Lesser J, Cheng SK, Isaacson SR, Sisti MB, Bruce JN, McKhann GM, Sheth SA, Lassman AB, Wang TJC.

J Neurooncol. 2018 Jan;136(2):281-287. doi: 10.1007/s11060-017-2651-1. Epub 2017 Nov 23.

PMID:
29170908
15.

Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.

Gan HK, Reardon DA, Lassman AB, Merrell R, van den Bent M, Butowski N, Lwin Z, Wheeler H, Fichtel L, Scott AM, Gomez EJ, Fischer J, Mandich H, Xiong H, Lee HJ, Munasinghe WP, Roberts-Rapp LA, Ansell PJ, Holen KD, Kumthekar P.

Neuro Oncol. 2018 May 18;20(6):838-847. doi: 10.1093/neuonc/nox202.

16.

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.

van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Bain E, Ansell PJ, Holen KD, Maag D, Reardon DA.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1209-1217. doi: 10.1007/s00280-017-3451-1. Epub 2017 Oct 26.

17.

Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.

Clarke J, Neil E, Terziev R, Gutin P, Barani I, Kaley T, Lassman AB, Chan TA, Yamada J, DeAngelis L, Ballangrud A, Young R, Panageas KS, Beal K, Omuro A.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):797-804. doi: 10.1016/j.ijrobp.2017.06.2466. Epub 2017 Jun 30.

18.

Comparing sequencing assays and human-machine analyses in actionable genomics for glioblastoma.

Wrzeszczynski KO, Frank MO, Koyama T, Rhrissorrakrai K, Robine N, Utro F, Emde AK, Chen BJ, Arora K, Shah M, Vacic V, Norel R, Bilal E, Bergmann EA, Moore Vogel JL, Bruce JN, Lassman AB, Canoll P, Grommes C, Harvey S, Parida L, Michelini VV, Zody MC, Jobanputra V, Royyuru AK, Darnell RB.

Neurol Genet. 2017 Jul 11;3(4):e164. doi: 10.1212/NXG.0000000000000164. eCollection 2017 Aug.

19.

Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.

Gan HK, van den Bent M, Lassman AB, Reardon DA, Scott AM.

Nat Rev Clin Oncol. 2017 Nov;14(11):695-707. doi: 10.1038/nrclinonc.2017.95. Epub 2017 Jul 4. Review.

PMID:
28675164
20.

NovoTTF: where to go from here?

Cloughesy TF, Lassman AB.

Neuro Oncol. 2017 May 1;19(5):605-608. doi: 10.1093/neuonc/nox014. No abstract available.

21.

An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.

Gittleman H, Lim D, Kattan MW, Chakravarti A, Gilbert MR, Lassman AB, Lo SS, Machtay M, Sloan AE, Sulman EP, Tian D, Vogelbaum MA, Wang TJC, Penas-Prado M, Youssef E, Blumenthal DT, Zhang P, Mehta MP, Barnholtz-Sloan JS.

Neuro Oncol. 2017 May 1;19(5):669-677. doi: 10.1093/neuonc/now208.

22.

Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.

Reardon DA, Lassman AB, van den Bent M, Kumthekar P, Merrell R, Scott AM, Fichtel L, Sulman EP, Gomez E, Fischer J, Lee HJ, Munasinghe W, Xiong H, Mandich H, Roberts-Rapp L, Ansell P, Holen KD, Gan HK.

Neuro Oncol. 2017 Jul 1;19(7):965-975. doi: 10.1093/neuonc/now257.

23.

Biomarkers in NOA-04: another piece to the puzzle.

Lassman AB, Cloughesy TF.

Neuro Oncol. 2016 Nov;18(11):1467-1469. No abstract available.

24.

Hypofractionated radiation therapy versus standard fractionated radiation therapy with concurrent temozolomide in elderly patients with newly diagnosed glioblastoma.

Wang TJC, Wu CC, Jani A, Estrada J, Ung T, Chow DS, Soun JE, Saad S, Qureshi YH, Gartrell R, Saadatmand HJ, Saraf A, Garrett MD, Grubb C, Isaacson SR, Cheng SK, Sisti MB, Bruce JN, Sheth SA, Lassman AB, Iwamoto FM, McKhann GM 2nd.

Pract Radiat Oncol. 2016 Sep-Oct;6(5):306-314. doi: 10.1016/j.prro.2015.12.001. Epub 2015 Dec 4.

PMID:
26952813
25.

Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, Hunger S, Krishnamurthi SS, Lassman AB, Markham MJ, Mayer E, Neuss M, Pal SK, Richardson LC, Schilsky R, Schwartz GK, Spriggs DR, Villalona-Calero MA, Villani G, Masters G.

J Clin Oncol. 2016 Mar 20;34(9):987-1011. doi: 10.1200/JCO.2015.65.8427. Epub 2016 Feb 4. No abstract available.

26.

A Modern Radiotherapy Series of Survival in Hispanic Patients with Glioblastoma.

Wu CC, Wang TJ, Jani A, Estrada JP, Ung T, Chow DS, Soun JE, Saad S, Qureshi YH, Gartrell R, Saadatmand HJ, Saraf A, Garrett MD, Grubb CS, Isaacson SR, Cheng SK, Sisti MB, Bruce JN, Sheth SA, Lassman AB, McKhann GM 2nd.

World Neurosurg. 2016 Apr;88:260-9. doi: 10.1016/j.wneu.2015.12.081. Epub 2015 Dec 31.

PMID:
26746331
27.

Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery.

Grubb CS, Jani A, Wu CC, Saad S, Qureshi YH, Nanda T, Yaeh A, Rozenblat T, Sisti MB, Bruce JN, McKhann GM 2nd, Sheth SA, Lesser J, Cheng SK, Isaacson SR, Lassman AB, Connolly EP, Wang TJ.

J Neurooncol. 2016 Mar;127(1):103-10. doi: 10.1007/s11060-015-2014-8. Epub 2015 Nov 28.

PMID:
26615564
28.

Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?

Lassman AB.

CNS Oncol. 2015;4(5):341-6. doi: 10.2217/cns.15.36. Epub 2015 Nov 6. Review.

29.

Timing of Adjuvant Radiotherapy in Glioblastoma Patients: A Single-Institution Experience With More Than 400 Patients.

Wang TJ, Jani A, Estrada JP, Ung TH, Chow DS, Soun JE, Saad S, Qureshi YH, Gartrell R, Isaacson SR, Cheng SK, McKhann GM 2nd, Bruce JN, Lassman AB, Sisti MB.

Neurosurgery. 2016 May;78(5):676-82. doi: 10.1227/NEU.0000000000001036.

PMID:
26440447
30.

Control of brain metastases from radioresistant tumors treated by stereotactic radiosurgery.

Yaeh A, Nanda T, Jani A, Rozenblat T, Qureshi Y, Saad S, Lesser J, Lassman AB, Isaacson SR, Sisti MB, Bruce JN, McKhann GM 2nd, Wang TJ.

J Neurooncol. 2015 Sep;124(3):507-14. doi: 10.1007/s11060-015-1871-5. Epub 2015 Aug 2.

PMID:
26233247
31.

Indications for Treatment: Is Observation or Chemotherapy Alone a Reasonable Approach in the Management of Low-Grade Gliomas?

Schaff LR, Lassman AB.

Semin Radiat Oncol. 2015 Jul;25(3):203-9. doi: 10.1016/j.semradonc.2015.02.008. Epub 2015 Feb 23. Review.

32.

Radiotherapy and temozolomide for anaplastic astrocytic gliomas.

Nayak L, Panageas KS, Reiner AS, Huse JT, Pentsova E, Braunthal SG, Abrey LE, DeAngelis LM, Lassman AB.

J Neurooncol. 2015 May;123(1):129-34. doi: 10.1007/s11060-015-1771-8. Epub 2015 Apr 29.

33.

A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.

Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL, Wen PY.

Clin Cancer Res. 2015 Aug 15;21(16):3610-8. doi: 10.1158/1078-0432.CCR-14-3220. Epub 2015 Apr 24.

34.

Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?

Wang TJ, Saad S, Qureshi YH, Jani A, Nanda T, Yaeh AM, Rozenblat T, Sisti MB, Bruce JN, McKhann GM, Lesser J, Halmos B, Stoopler MB, Lassman AB, Cheng SK, Isaacson SR.

Neuro Oncol. 2015 Jul;17(7):1022-8. doi: 10.1093/neuonc/nov043. Epub 2015 Apr 24.

35.

Opsoclonus-myoclonus syndrome in a patient with an anaplastic oligoastrocytoma.

Gold CA, Lassman AB, Odia Y.

J Neurooncol. 2015 Jun;123(2):315-6. doi: 10.1007/s11060-015-1783-4. Epub 2015 Apr 12. No abstract available.

PMID:
25864100
36.

The Energy Index Does Not Affect Local Control of Brain Metastases Treated by Gamma Knife Stereotactic Radiosurgery.

Jani A, Rozenblat T, Yaeh AM, Nanda T, Saad S, Qureshi YH, Feng W, Sisti MB, Bruce JN, McKhann GM 2nd, Lesser J, Lassman AB, Isaacson SR, Wang TJ.

Neurosurgery. 2015 Jul;77(1):119-25; discussion 125. doi: 10.1227/NEU.0000000000000750.

PMID:
25830600
37.

Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627).

Lassman AB, Pugh SL, Gilbert MR, Aldape KD, Geinoz S, Beumer JH, Christner SM, Komaki R, DeAngelis LM, Gaur R, Youssef E, Wagner H, Won M, Mehta MP.

Neuro Oncol. 2015 Jul;17(7):992-8. doi: 10.1093/neuonc/nov011. Epub 2015 Mar 10.

38.

Outcomes of gamma knife radiosurgery, bi-modality & tri-modality treatment regimens for patients with one or multiple brain metastases: the Columbia University Medical Center experience.

Wang TJ, Saad S, Qureshi YH, Jani A, Isaacson SR, Sisti MB, Bruce JN, McKhann GM 2nd, Lesser J, Cheng SK, Clifford Chao KS, Lassman AB.

J Neurooncol. 2015 Apr;122(2):399-408. doi: 10.1007/s11060-015-1728-y. Epub 2015 Feb 17.

PMID:
25687652
39.

Factorial clinical trials: a new approach to phase II neuro-oncology studies.

Iwamoto FM, Lassman AB.

Neuro Oncol. 2015 Feb;17(2):174-6. doi: 10.1093/neuonc/nou314. Epub 2014 Dec 1. No abstract available.

40.

Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.

Omuro A, Beal K, Gutin P, Karimi S, Correa DD, Kaley TJ, DeAngelis LM, Chan TA, Gavrilovic IT, Nolan C, Hormigo A, Lassman AB, Mellinghoff I, Grommes C, Reiner AS, Panageas KS, Baser RE, Tabar V, Pentsova E, Sanchez J, Barradas-Panchal R, Zhang J, Faivre G, Brennan CW, Abrey LE, Huse JT.

Clin Cancer Res. 2014 Oct 1;20(19):5023-31. doi: 10.1158/1078-0432.CCR-14-0822. Epub 2014 Aug 8.

41.

Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.

Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A, Drappatz J, Lee EQ, Purow B, Plotkin SR, Batchelor T, Abrey LE, Omuro A.

Neuro Oncol. 2015 Jan;17(1):116-21. doi: 10.1093/neuonc/nou148. Epub 2014 Aug 6.

42.

Fetal radiation monitoring and dose minimization during intensity modulated radiation therapy for glioblastoma in pregnancy.

Horowitz DP, Wang TJ, Wuu CS, Feng W, Drassinower D, Lasala A, Pieniazek R, Cheng S, Connolly EP, Lassman AB.

J Neurooncol. 2014 Nov;120(2):405-9. doi: 10.1007/s11060-014-1565-4. Epub 2014 Aug 6.

PMID:
25096798
43.

Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.

Panageas KS, Reiner AS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Lassman AB.

Neuro Oncol. 2014 Nov;16(11):1541-6. doi: 10.1093/neuonc/nou083. Epub 2014 Jul 4.

44.

Semiautomated volumetric measurement on postcontrast MR imaging for analysis of recurrent and residual disease in glioblastoma multiforme.

Chow DS, Qi J, Guo X, Miloushev VZ, Iwamoto FM, Bruce JN, Lassman AB, Schwartz LH, Lignelli A, Zhao B, Filippi CG.

AJNR Am J Neuroradiol. 2014 Mar;35(3):498-503. doi: 10.3174/ajnr.A3724. Epub 2013 Aug 29.

45.

Oligodendrogliomas: questions answered, answers questioned.

Lassman AB.

Oncology (Williston Park). 2013 Apr;27(4):326, 328. No abstract available.

46.

Steroid management in newly diagnosed glioblastoma.

Deutsch MB, Panageas KS, Lassman AB, Deangelis LM.

J Neurooncol. 2013 May;113(1):111-6. doi: 10.1007/s11060-013-1096-4. Epub 2013 Mar 6.

PMID:
23462855
47.

Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept.

Shonka N, Piao Y, Gilbert M, Yung A, Chang S, DeAngelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, de Groot J.

Target Oncol. 2013 Jun;8(2):117-25. doi: 10.1007/s11523-013-0254-0. Epub 2013 Jan 24.

48.

Success at last: a molecular factor that informs treatment.

Lassman AB.

Curr Oncol Rep. 2013 Feb;15(1):47-55. doi: 10.1007/s11912-012-0281-5.

PMID:
23247800
49.

Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.

Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I.

Neuro Oncol. 2013 Feb;15(2):242-50. doi: 10.1093/neuonc/nos295. Epub 2012 Dec 14.

50.

Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional status.

Reyngold M, Lassman AB, Chan TA, Yamada Y, Gutin PH, Beal K.

J Neurooncol. 2012 Dec;110(3):369-74. doi: 10.1007/s11060-012-0972-7. Epub 2012 Sep 16.

PMID:
22983908

Supplemental Content

Loading ...
Support Center